Cancer TOS-358 demonstrates efficacy in wild-type and mutant PI3Kα cancer models Nov. 14, 2022 Researchers from Totus Medicines Inc. presented preclinical data for the potent and selective covalent inhibitor of phosphoinositide 3-kinase α (PI3Kα), TOS-358, which is being developed for the treatment of cancer.Read More
